CBAY - CymaBay Therapeutics shares long-term bio marker data for liver disease therapy

CymaBay Therapeutics (NASDAQ:CBAY) announced long-term data from an open-label trial of seladelpar, the company’s experimental therapy for primary biliary cholangitis (PBC), indicating its efficacy following the treatment of one and two years. The results were shared in an oral presentation at the Liver Meeting Digital Experience 2021 American Association for the Study of Liver Diseases (AASLD). The primary endpoint of the study was the percent change in alkaline phosphatase (ALP) from baseline at one and two years, the mean value of which stood at -42% and -50%, respectively. The oral treatment appeared safe and well-tolerated, the company said. The results suggest that “seladelpar may provide an effective long-term treatment option for patients with PBC and may signal that the benefits gleaned may be sustained and perhaps even improve over a 2-year period,” CymaBay (CBAY) Chief Medical Officer, remarked. In Aug. 2020, the company said its Phase 3 clinical trial for seladelpar

For further details see:

CymaBay Therapeutics shares long-term bio marker data for liver disease therapy